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Abstract
Walker-Warburg Syndrome (WWS) is a rare form of autosomal recessive congenital muscular
dystrophy associated with brain and eye abnormalities. WWS has a worldwide distribution. The
overall incidence is unknown but a survey in North-eastern Italy has reported an incidence rate of
1.2 per 100,000 live births. It is the most severe form of congenital muscular dystrophy with most
children dying before the age of three years. WWS presents at birth with generalized hypotonia,
muscle weakness, developmental delay with mental retardation and occasional seizures. It is
associated with type II cobblestone lissencephaly, hydrocephalus, cerebellar malformations, eye
abnormalities and congenital muscular dystrophy characterized by hypoglycosylation of α-
dystroglycan. Several genes have been implicated in the etiology of WWS, and others are as yet
unknown. Several mutations were found in the Protein O-Mannosyltransferase 1 and 2 (POMT1 and
POMT2) genes, and one mutation was found in each of the fukutin and fukutin-related protein
(FKRP) genes. Laboratory investigations usually show elevated creatine kinase, myopathic/
dystrophic muscle pathology and altered α-dystroglycan. Antenatal diagnosis is possible in families
with known mutations. Prenatal ultrasound may be helpful for diagnosis in families where the
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Walker-Warburg Syndrome (WWS) is a genetically heter-
ogeneous disease presenting with congenital muscular
dystrophy, type II lissencephaly, hydrocephalus, cerebel-
lar malformations and eye abnormalities [1-4]. So far,
only 10%–20% of cases can be confirmed by DNA analy-
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sis of mutations in the Protein O-Mannosyltransferase 1
(POMT1) gene [5-7]. DNA analysis in other genes besides
POMT1 can be confirmative: fukutin [8,9]; FKRP [10] and
POMT2 [11].
Epidemiology
WWS is a rare disease with a worldwide distribution; how-
ever, the overall incidence is unknown. A survey in north-
eastern Italy has reported an incidence rate of 1.2 per
100,000 live births [12].
Clinical description
WWS is the most severe congenital muscular dystrophy
(CMD). Symptoms and signs are already present at birth
and early infancy, and occasionally can be detected prena-
tally with imaging techniques. WWS is associated with
generalized hypotonia, muscle weakness, developmental
delay with mental retardation and, in some children, sei-
zures. There may be a variety of anterior eye anomalies
(cataracts, shallow anterior chamber, microcornea and
microphthalmia, and lens defects) and a spectrum of pos-
terior eye anomalies (retinal detachment or dysplasia,
hypoplasia or atrophy of the optic nerve and macula and
coloboma). Glaucoma or buphthalmos may be present.
Brain abnormalities include migrational defect with type
II lissencephaly (cobblestone type), hydrocephalus, ver-
mal or general cerebellar hypoplasia and flat brainstem
with small pyramids. White matter shows hypomyelina-
tion. Additional brain anomalies such as hypoplasia/
agenesis of corpus callosum, occipital encephalocele and
Dandy-Walker malformation have been described. Other
recognized associated anomalies are small penis, unde-
scended testes, and, rarely, other facial dysmorphic fea-
tures such as low set or prominent ears and cleft lip or
palate.
Laboratory investigations usually show elevated creatine
kinase, myopathic/dystrophic muscle pathology and
altered α-dystroglycan.
Etiology
The dystrophin glycoprotein complex (DGC) is an assem-
bly of proteins spanning the sarcolemma of skeletal mus-
cle cells [13-15]. Defects in the DGC appear to play critical
roles in several muscular dystrophies due to disruption of
basement membrane organization [16,17]. Dystroglycan
(dystrophin-associated glycoprotein), a major compo-
nent of the DGC, is expressed in many cell types, and is
synthesized as a precursor propeptide that is post-transla-
tionally cleaved and differentially glycosylated to yield α-
and β-dystroglycans. There is evidence suggesting that the
tetrasaccharide NeuAcα2, 3Galβ1, 4GlcNAcβ1, 2Manα1-
O-Ser/Thr present on α-dystroglycan is required for the
binding of laminin and other ligands to α-dystroglycan
[18-20].
Mutations interfering with the binding of extracellular lig-
ands to α-dystroglycan may lead to weakened anchorage
of muscle fibers to the extracellular matrix with very early
(i.e., embryonic) and rapid muscle dysfunction and
necrosis [17]. This process is responsible for an etiologi-
cally heterogeneous group of autosomal recessive CMDs
with associated brain and eye abnormalities [5,21-28].
Immunohistochemical studies using antibodies against α-
dystroglycan (e.g. VIA4-1 directed against the glycans on
α-dystroglycan) have revealed that these CMDs are associ-
ated with deficient immunostaining of α-dystroglycan in
the basal lamina of skeletal muscles [29-33]. The data
indicate that α-dystroglycan is underglycosylated in mus-
cle from these patients [34].
A genome-wide linkage analysis in 10 consanguineous
families with WWS indicated the existence of at least three
WWS loci [6]. Since protein O-mannoside β1,2-N-
acetylglucosaminyltransferase (POMGnT1) had recently
been implicated as the cause of muscle-eye-brain disease
(MEB) [35-37], Beltran-Valero de Bernabe et al. [6]
screened WWS patients for mutations in the gene encod-
ing protein O-mannosyltransferase (POMT) that attaches
mannose via a O-glycosidic link to the Ser/Thr residues of
α-dystroglycan, thereby synthesizing the substrate for
POMGnT1. Homozygous mutations at the POMT1 locus
on chromosome 9q34 were found in 5 out of 15 consan-
guineous families with WWS. Sequencing of the POMT1
gene revealed mutations in 6 out of 30 unrelated patients
with WWS [6]. Of the five mutations identified, two were
nonsense mutations, two were frameshift mutations and
one was a missense mutation. Other mutations and phe-
notype-genotype correlations were reported in 2006 [38].
More severe phenotypes were associated with highly dis-
ruptive homozygous mutations, while mild compound
heterozygous mutations in one or both alleles were asso-
ciated with a less severe phenotype and longer life span.
In another series of 30 patients with classic WWS, two
potential novel heterozygous mutations in the POMT1
gene were found in two patients from non-consanguine-
ous parents [39]. However, the other 28 patients failed to
show any POMT1 mutations. Linkage analysis in six con-
sanguineous families with WWS showed that defective
POMT1 was an uncommon cause of WWS in this popula-
tion (the incidence of coding region mutations was less
than 7%).
One other child with the WWS phenotype was reported to
have a homozygous null mutation in the fukutin gene and
another child a homozygous C953T missense mutation in
the FKRP gene [8,10]. A fourth causative gene for WWS
was found in 2005, when three homozygous mutations in
the POMT2  gene were detected in WWS patients from
three families [7].Orphanet Journal of Rare Diseases 2006, 1:29 http://www.OJRD.com/content/1/1/29
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In all tissues tested, POMT1 mRNA is expressed as a 3.1 kb
transcript, with highest levels in the testes and fetal brain.
Alternative splicing of several exons in all tissues predicts
the generation of several protein isoforms. A method for
measuring POMT activity in mammalian cells has been
developed [37]. However, recombinant POMT1 was
found to be inactive. It turns out that the human genome
contains two genes encoding POMT (POMT1  and
POMT2). Neither recombinant protein by itself shows
enzyme activity. Mixing of recombinant forms of the two
proteins also fails to result in an active enzyme. The two
genes must be co-expressed to obtain an active POMT
enzyme complex [40-42].
Homozygous inactivation of the POMT1  gene in the
mouse is embryonic lethal with developmental arrest
around embryonic day (E) 7.5 and death between E7.5
and E9.5 [43]. The POMT1(-/-) embryos present defects in
the formation of Reichert's membrane, the first basement
membrane to form in the embryo. The failure of this
membrane to form appears to be the result of abnormal
glycosylation and maturation of dystroglycan that may
impair recruitment of laminin, a structural component
required for the formation of Reichert's membrane in
rodents.
Diagnostic methods and criteria
The diagnosis is established on the basis of four criteria:
￿ congenital muscular dystrophy characterized by
hypoglycosylation of α-dystroglycan
￿ high creatine kinase level
￿ anterior or posterior eye anomalies
￿ migrational brain defect with type II lissencephaly and
hydrocephalus
￿ abnormal brainstem/cerebellum
Mutations or gene loci are currently unknown in majority
of patients. Only 10 – 20% of cases have a mutation in the
POMT1, POMT2, fukutin or FKRP genes.
The diagnostic criteria for WWS were established on the
basis of data obtained from 21 patients and an additional
42 patients from the literature [5]. Four abnormalities
were present in all patients checked for these anomalies:
type II lissencephaly (21/21), cerebellar malformation
(20/20), retinal malformation (18/18), and CMD (14/
14). Two other frequently observed abnormalities, ven-
tricular dilatation with or without hydrocephalus (20/21)
and anterior chamber malformation (16/21), were help-
ful but not obligatory for diagnosis because they were not
constant. All other abnormalities occurred less frequently.
Congenital macrocephaly with hydrocephalus (11/19)
was more common than congenital microcephaly (3/19).
Dandy-Walker malformation (10/19) was sometimes
associated with posterior cephalocele (5/21). Additional
abnormalities included slit-like ventricles (1/21), micro-
phthalmia (8/21), ocular colobomas (3/15), congenital
cataracts (7/20), and genital anomalies in males (5/8).
Differential diagnosis
The differential diagnoses include:
￿ Fukuyama congenital muscular dystrophy (FCMD)
￿ CMD type 1C
￿ CMD type 1D
￿ Muscle-eye-brain disease (MEB)
￿ Congenital muscular dystrophies without brain and eye
abnormalities
FCMD and MEB are associated with similar but less severe
brain and eye changes and CMD. Patients with CMD type
1C may have variable findings on brain magnetic reso-
nance imaging (MRI) and eye exam. The only patient with
CMD type 1D reported so far has milder brain abnormal-
ities than those seen in WWS.
Genetic counseling
WWS is an autosomal recessive disorder. In families with
one affected child, the risk of having another child with
the disease is 25%.
Antenatal diagnosis
Antenatal molecular diagnosis might be possible in fami-
lies with known mutations. Antenatal ultrasound can also
be helpful in families in whom the molecular defect is
unknown. Hydrocephalus has been detected by ultra-
sound as early as at 13 weeks of gestation [44] and occip-
ital encephalocele, not always present, has been detected
at 18 weeks of gestation [45].
Management including treatment
Management is only supportive and preventive. If seizures
develop, they usually need to be treated with anticonvul-
sants. A few children require a neurosurgical procedure
such as shunting of hydrocephalus or encephalocele oper-
ation. Physical therapy can be offered to facilitate devel-
opment or prevent worsening of contractures although its
efficacy has not been established. Feeding needs to be
monitored and supplemental nasogastric or gastric tube
feeding provided in some cases. Detailed eye assessment
is also needed.Orphanet Journal of Rare Diseases 2006, 1:29 http://www.OJRD.com/content/1/1/29
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Prognosis
The condition is usually lethal within the first few months
of life, with almost all children dying by the age of three.
Unresolved questions
There are no known candidate genes for 80%–90% of
children with WWS. Although the POMT1 gene involved
in WWS implies a defect in O-mannosylation of α-dystro-
glycan, the exact pathophysiology of this disorder is not
fully understood. As new genetic defects associated with
WWS are reported, a better genotype-phenotype correla-
tion should be established.
Other interesting issues
The following research papers have helped to shed light
on Walker-Warburg syndrome:
Role of dystroglycan in pathogenesis [46]
In mice, brain-selective deletion of dystroglycan is suffi-
cient to cause CMD-like brain malformations, including
disarray of cerebral cortical layering, fusion of cerebral
hemispheres and cerebellar folia, and aberrant migration
of granule cells. Additionally, high-affinity binding to
laminin is lost, and there are discontinuities in the pial
surface basal lamina (glia limitans) that probably under-
lie the neuronal migration errors. Furthermore, mutant
mice have severely blunted hippocampal long-term
potentiation with electrophysiologic characterization
indicating that dystroglycan might have a postsynaptic
role in learning and memory.
The data strongly support the hypothesis that defects in
dystroglycan are central to the pathogenesis of structural
and functional brain abnormalities seen in CMD.
Pathogenetic mechanisms underlying degeneration [47]
Immunohistochemical and electron microscopy were car-
ried out on muscle obtained by biopsy from a patient with
WWS carrying a homozygous frameshift mutation in
POMT1. The α-dystroglycan glycosylated epitope was not
detected in muscle fibers or intramuscular peripheral
nerves. Laminin-α2 chain and perlecan were reduced in
muscle fibers but well preserved in intramuscular periph-
eral nerves. The basal lamina in several muscle fibers
showed discontinuities and detachment from the plasma-
lemma. Most nuclei, including myonuclei and satellite
cell nuclei, showed detachment or complete absence of
peripheral heterochromatin from the nuclear envelope.
Apoptotic changes were detected in 3% of muscle fibers.
The particular combination of basal lamina and nuclear
changes suggests that a complex pathogenetic mecha-
nism, involving several subcellular compartments, under-
lies the muscle degenerative process in WWS.
Genetic heterogeneity [48]
Immunohistochemistry and immunoblotting showed
almost complete absence of α-dystroglycan and a mild
reduction of laminin-α2 in two patients with WWS. In
contrast, immunohistochemical labeling of perlecan and
collagen VI was normal. Linkage analysis excluded the
POMT1 locus, confirming that WWS is a genetically heter-
ogeneous condition.
It was suggested that disruption of the α-dystroglycan/
laminin-α2 axis in the basal lamina may play a role in the
degeneration of muscle fibers in WWS patients who do
not have a mutation in POMT1.
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